← Back to searchRecruitingRecruiting
Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)
NCT06116019 · Charite University, Berlin, Germany
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Prospective Study on Online Adaptive Radiotherapy (ART) Using the ETHOS Linear Accelerator for Various Tumor Entities and the Feasibility of Integrating Multi-Parametric Patient Data Into the Adaptive Workflow
About this study
The study focuses on the scientific and clinical evaluation of online adaptive radiotherapy (ART) using the Varian/SHS ETHOS treatment system. In this study, radiation treatment plans are dynamically adjusted on a daily basis over several weeks of therapy to account for anatomical shifts in either the tumour or adjacent normal tissue - a capability that has been difficult to achieve due to technical limitations. With the ETHOS accelerator, such real-time adjustments can be made based on cone beam computed tomography (CBCT). This is a prospective observational study with the primary objective of investigating the feasibility and acceptability of performing ART with ETHOS for different tumour entities. The study will also evaluate the feasibility of integrating multi-parametric data sets into the ART workflow, such as standardised electronic feedback on treatment toxicity from both patients (ePROMS) and physicians (ePRT).
Eligibility criteria
Inclusion Criteria:
* Adult patients (\>18 years)
* All tumor entities with an indication for radiotherapy and/or chemoradiotherapy
* Signed informed consent
Exclusion Criteria:
* Pregnancy
* Patients who are not capable of giving consent
Study design
Enrollment target: 649 participants
Age groups: adult, older_adult
Timeline
Starts: 2023-10-11
Estimated completion: 2027-10-09
Last updated: 2023-11-03
Interventions
Radiation: Online adaptive radiation therapy
Primary outcomes
- • Number of Successfully Completed Adaptive Radiotherapy Sessions in Patients with Various Tumor Entities (Throughout the treatment period, up to 6 weeks.)
Sponsor
Charite University, Berlin, Germany · other
Contacts & investigators
ContactGoda Kalinauskaite, MD · contact · goda.kalinauskaite@charite.de · +49 30 450 527318
ContactCarolin Senger, MD · contact · carolin.senger@charite.de · +49 30 450 527318
All locations (1)
Charité - UniversitätsmedizinRecruiting
Berlin, Germany